8 — Class I drug recall D-0234-2024
Ongoing recall by Pfizer Inc., reported 2024-01-24, distributed nationwide. Presence of Particulate Matter; identified as glass
| Recall number | D-0234-2024 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2023-12-21 |
| Classified | 2024-01-17 |
| Reported by FDA | 2024-01-24 |
| Distributed | Nationwide (US) |
| Quantity | 21,200 cartons |
| Reason classes | foreign material, specification failure |
| NDC | 00409-4916, 00409-4916-14, 00409-4916-24, 00409-6637, 00409-6637-14, 00409-6637-24 |
| Lot numbers | HA7295 |
| Expiration dates | 2025-03-01 |
Product
8.4 % Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL), Lifeshield, Glass ABBOJECT Unit of Use Syringe, Rx Only, 50 mL Syringe per Carton, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-6637-24 (carton), 0409-6637-14 (case).
Reason for recall
Presence of Particulate Matter; identified as glass
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0234-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.